Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTOEJX)

Drug Name
Acid-activated omeprazole Drug Info
Synonyms
Hydroxyfasudil; HYDROXYFASUDIL; 105628-72-6; Hydroxy-Fasudil; 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine; HA 1100; HA-1100; 1-[(1,2-DIHYDRO-1-OXO-5-ISOQUINOLINYL)SULFONYL]HEXAHYDRO-1H-1,4-DIAZEPINE; CHEMBL1233300; Hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-1H-1,4-diazepine; 5-(1,4-diazepane-1-sulfonyl)-1,2-dihydroisoquinolin-1-one; HYDROXYFASUDIL;5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one; 1H-1,4-Diazepine, hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-; HFS; 2etk; 2erz; AC1MI8J4; SCHEMBL123699
Cross-matching ID
PubChem CID
3064778
ChEBI ID
CHEMBL1233300
CAS Number
CAS 105628-72-6
TTD Drug ID
D0L1UK
VARIDT Drug ID
DR00804

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.24 0.00e+0 34/36 (94.44%) PCNA;RFC2;POLD2;...
Pyruvate metabolism 2.07 0.00e+0 41/47 (87.23%) DLD;PKM;ALDH3A2;...
Citrate cycle (TCA cycle) 2.05 0.00e+0 30/30 (100%) DLD;IDH3A;DLST;...
Oxidative phosphorylation 2.00 5.52e-3 93/133 (69.92%) ATP6V1D;ATP6V0E2;NDUFA5;...
Glycolysis / Gluconeogenesis 1.97 1.10e-2 56/67 (83.58%) DLD;ENO2;PKM;...
Nucleotide excision repair 1.88 1.10e-2 40/47 (85.11%) PCNA;RFC2;RAD23B;...
Cardiac muscle contraction 1.83 2.37e-2 64/87 (73.56%) TPM2;ATP2A2;ATP1A1;...
Mismatch repair 1.76 3.59e-2 22/23 (95.65%) PCNA;RFC2;POLD2;...
Legionellosis -1.79 2.92e-2 51/57 (89.47%) CXCL2;CXCL1;CASP1;...
Viral protein interaction with cytokine and cytokine re... -1.79 3.43e-2 84/100 (84%) CXCR1;IL2RG;CCR10;...
NF-kappa B signaling pathway -1.88 3.05e-3 90/104 (86.54%) TAB2;TRADD;CXCL2;...
Steroid biosynthesis -1.93 0.00e+0 19/20 (95%) LBR;DHCR7;MSMO1;...
Mineral absorption -2.00 0.00e+0 48/60 (80%) SLC34A1;SLC30A1;HEPH;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 6H, 24H